$EXEL

Aftab Dana sold $2.2M of EXEL

Aftab Dana (EVP, Research and Development) sold 43,451 shares of EXELIXIS, INC. (EXEL) at $50.35 ($2.19M total) on 2026-05-26.

Original reporting
SEC EDGAR · Aftab Dana
Published May 28, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 8:40 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$EXEL
Neutral
medium confidence
Mentioned
$EXEL
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EXELNeutralLow
01

Why it matters

Aftab Dana, EVP Research and Development, sold $2.19M of EXEL shares in an open-market transaction; the disclosure may slightly influence sentiment but does not introduce new operational or financial information about EXEL.

02

Market read

Traders may note the insider sale for sentiment monitoring, but there is no accompanying fundamental catalyst in the text.

03

What to watch

The absence of a stated 10b5-1 plan could raise speculation, but the filing provides no rationale for the sale or any link to upcoming catalysts.

Relevance 6/10Novelty 3/10Timing: Filed 2026-05-28, transaction dated 2026-05-26.

Background

The article is a SEC Form 4 insider transaction disclosure for EXELIXIS, Inc.

Company-level read

Ticker impact

$EXELNeutralMedium confidence
Context

EXELIXIS Form 4 shows EVP R&D Aftab Dana sold 43,451 shares at $50.35 on 2026-05-26 for about $2.19M.

Expected impact

Likely limited near-term impact; any effect is more sentiment-driven than thesis-changing.

Evidence & confidence

The filing is a routine insider transaction with no 10b5-1 plan and no accompanying company-specific news (earnings, guidance, deal, or regulatory action).

Market effects

No clear sector read-through; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Insider sales are often liquidity-driven and may not reflect negative expectations, especially without any other negative company-specific disclosures.

Key entities

  • EXELIXIS, INC.

    Company whose insider transaction is disclosed on Form 4.

  • Aftab Dana

    EVP, Research and Development who sold 43,451 shares.

Related articles

$EXELHigh

EXELIXIS, INC. (EXEL): Results of Operations and Financial Condition

EXELIXIS, INC. (EXEL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 5 exel20260630exhibit991.htm EX-99.1 Document Exhibit 99.1 Contacts: Chris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 csenner@exelixis.com Andrew Peters SVP, Strategy & Investor Relations Exelixis, Inc. 650-837-7248 apeters@exelixis.com Exelixis Announces

$EXELMed

EXEL Industries: Q3 2025-2026 revenue -18.7%

EXEL Industries reported Q3 FY2025-2026 revenue of €229.2m, down 18.7% year on year, or -18.0% at constant FX and scope, citing lower agricultural equipment volumes. Agricultural Spraying fell 17.1%, Sugar Beet Harvesting 35.6%, Leisure 14.2%, and Industry 16.7%. The company expects no significant cycle recovery before H2 FY2026-2027.

$EXELMedAI 9/10

If Decades of History Tell Us Anything, This Biotech Near $50 Is Primed to Skyrocket

Exelixis reported Q1 2026 results that beat consensus, with non-GAAP EPS of $0.87 (up 14.02% vs. expectations) on revenue of $610.81 million (up 9.97% YoY). The company said CABOMETYX franchise revenue rose 12.5% YoY to $764 million and authorized a $750 million buyback through Dec. 31, 2027. Exelixis also has a Dec. 3, 2026 PDUFA decision for zanzalintinib in metastatic colorectal cancer.